Literature DB >> 25954598

Healing after death: antitumor immunity induced by oncolytic adenoviral therapy.

Hong Jiang1, Juan Fueyo1.   

Abstract

We recently evaluated the capacity of Delta-24-RGD oncolytic adenovirus to trigger an antitumor immune response in a syngeneic mouse glioma model. This virotherapy elicited immunity against both tumor-associated antigens and viral antigens. An immunogenic cell death accompanied by pathogen- or damage- associated patterns (PAMPs and DAMPs) induced by the virus may be responsible for the adenoviral-mediated antitumor effect.

Entities:  

Keywords:  antitumor immunity; danger (or damage)-associated molecular patterns (DAMPs); immunogenic cell death; oncolytic adenovirus; pathogen-associated patterns (PAMPs)

Year:  2014        PMID： 25954598      PMCID： PMC4355947          DOI： 10.4161/21624011.2014.947872

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Endogenous MHC class II processing of a viral nuclear antigen after autophagy.

Authors:  Casper Paludan; Dorothee Schmid; Markus Landthaler; Martina Vockerodt; Dieter Kube; Thomas Tuschl; Christian Münz
Journal:  Science       Date:  2004-12-09       Impact factor: 47.728

Review 2.  Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses.

Authors:  Jonathan W Yewdell
Journal:  Immunity       Date:  2006-10       Impact factor: 31.745

Review 3.  The interplay between pathogen-associated and danger-associated molecular patterns: an inflammatory code in cancer?

Authors:  Monica Escamilla-Tilch; Georgina Filio-Rodríguez; Rosario García-Rocha; Ismael Mancilla-Herrera; Nicholas Avrion Mitchison; Juan Alberto Ruiz-Pacheco; Francisco Javier Sánchez-García; Daniela Sandoval-Borrego; Ernesto Antonio Vázquez-Sánchez
Journal:  Immunol Cell Biol       Date:  2013-10-08       Impact factor: 5.126

4.  Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death.

Authors:  Hong Jiang; Candelaria Gomez-Manzano; Hiroshi Aoki; Marta M Alonso; Seiji Kondo; Frank McCormick; Jing Xu; Yasuko Kondo; B Nebiyou Bekele; Howard Colman; Frederick F Lang; Juan Fueyo
Journal:  J Natl Cancer Inst       Date:  2007-09-11       Impact factor: 13.506

5.  Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity.

Authors:  Hong Jiang; Erin J White; Christian I Ríos-Vicil; Jing Xu; Candelaria Gomez-Manzano; Juan Fueyo
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

Review 6.  Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies.

Authors:  Samuel T Workenhe; Karen L Mossman
Journal:  Mol Ther       Date:  2013-10-19       Impact factor: 11.454

Review 7.  Viral subversion of immunogenic cell death.

Authors:  Oliver Kepp; Laura Senovilla; Lorenzo Galluzzi; Theocharis Panaretakis; Antoine Tesniere; Frederic Schlemmer; Frank Madeo; Laurence Zitvogel; Guido Kroemer
Journal:  Cell Cycle       Date:  2009-03-26       Impact factor: 4.534

Review 8.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

9.  Immunogenic cell death in radiation therapy.

Authors:  Lorenzo Galluzzi; Oliver Kepp; Guido Kroemer
Journal:  Oncoimmunology       Date:  2013-10-10       Impact factor: 8.110

10.  Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model.

Authors:  Hong Jiang; Karen Clise-Dwyer; Kathryn E Ruisaard; Xuejun Fan; Weihua Tian; Joy Gumin; Martine L Lamfers; Anne Kleijn; Frederick F Lang; Wai-Kwan Alfred Yung; Luis M Vence; Candelaria Gomez-Manzano; Juan Fueyo
Journal:  PLoS One       Date:  2014-05-14       Impact factor: 3.240
  10 in total
  19 in total

Review 1.  Trial Watch-Oncolytic viruses and cancer therapy.

Authors:  Jonathan Pol; Aitziber Buqué; Fernando Aranda; Norma Bloy; Isabelle Cremer; Alexander Eggermont; Philippe Erbs; Jitka Fucikova; Jérôme Galon; Jean-Marc Limacher; Xavier Preville; Catherine Sautès-Fridman; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

Review 2.  Regulated cell death and adaptive stress responses.

Authors:  Lorenzo Galluzzi; José Manuel Bravo-San Pedro; Oliver Kepp; Guido Kroemer
Journal:  Cell Mol Life Sci       Date:  2016-04-05       Impact factor: 9.261

3.  First oncolytic virus approved for melanoma immunotherapy.

Authors:  Jonathan Pol; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

4.  An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.

Authors:  Yuefeng Yang; Weidong Xu; Di Peng; Hao Wang; Xiaoyan Zhang; Hua Wang; Fengjun Xiao; Yitan Zhu; Yuan Ji; Kamalakar Gulukota; Donald L Helseth; Kathy A Mangold; Megan Sullivan; Karen Kaul; Edward Wang; Bellur S Prabhakar; Jinnan Li; Xuejie Wu; Lisheng Wang; Prem Seth
Journal:  Hum Gene Ther       Date:  2019-07-01       Impact factor: 5.695

Review 5.  Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints.

Authors:  Hong Jiang; Candelaria Gomez-Manzano; Yisel Rivera-Molina; Frederick F Lang; Charles A Conrad; Juan Fueyo
Journal:  Curr Opin Virol       Date:  2015-04-13       Impact factor: 7.090

Review 6.  Immunotherapy for Neuro-oncology.

Authors:  Nazanin K Majd; Pushan R Dasgupta; John F de Groot
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.

Authors:  Hong Jiang; Yisel Rivera-Molina; Candelaria Gomez-Manzano; Karen Clise-Dwyer; Laura Bover; Luis M Vence; Ying Yuan; Frederick F Lang; Carlo Toniatti; Mohammad B Hossain; Juan Fueyo
Journal:  Cancer Res       Date:  2017-05-31       Impact factor: 12.701

8.  Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma.

Authors:  Yusuke Mochizuki; Hiroshi Tazawa; Koji Demiya; Miho Kure; Hiroya Kondo; Tadashi Komatsubara; Kazuhisa Sugiu; Joe Hasei; Aki Yoshida; Toshiyuki Kunisada; Yasuo Urata; Shunsuke Kagawa; Toshifumi Ozaki; Toshiyoshi Fujiwara
Journal:  Cancer Immunol Immunother       Date:  2020-11-05       Impact factor: 6.968

Review 9.  Recent advances in oncolytic adenovirus therapies for cancer.

Authors:  Amanda Rosewell Shaw; Masataka Suzuki
Journal:  Curr Opin Virol       Date:  2016-07-02       Impact factor: 7.090

Review 10.  Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants.

Authors:  Adil Mohamed; Randal N Johnston; Maya Shmulevitz
Journal:  Viruses       Date:  2015-12-01       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.